Navigation Links
CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
Date:10/12/2009

KING OF PRUSSIA, Pa., Oct. 12 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Berinert® C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE), a rare and serious genetic disorder, in adult and adolescent patients. Berinert is the first and only therapy approved for this indication in the U.S. The approval is based on the results of the phase II/III prospective, double-blind placebo-controlled International Multi-center Prospective Angioedema C1-Inhibitor Trial (I.M.P.A.C.T.), which studied the efficacy and safety of C1-inhibitor (C1-INH) concentrate. The safety and efficacy of Berinert for prophylactic therapy have not been established.

"The FDA approval of Berinert marks an important milestone in CSL Behring's ongoing commitment to satisfying the unmet needs of patients with rare and serious disorders, such as hereditary angioedema," said Robert Lefebvre, Vice President and General Manager of U.S. Commercial Operations at CSL Behring. "As a leader in developing safe, effective and high-quality therapies, we are pleased to add to our rapidly growing portfolio a proven treatment that can make a positive difference in the lives of HAE patients and their families."

HAE is a genetic disorder caused by a deficiency of C1-INH and is inherited in an autosomal dominant manner. Symptoms of HAE include episodes of edema or swelling in the face and the abdomen. Patients who have abdominal attacks of HAE can experience episodes of severe pain, diarrhea, nausea, and vomiting caused by swelling of the intestinal wall. HAE attacks that involve the face can cause painful distortion and painful swelling. Diagnosis of HAE requires a blood test to confirm low or abn
'/>"/>

SOURCE CSL Behring
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
2. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
3. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
4. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
5. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
6. Child Neurology Foundation Announces the Launch of Infantilespasmsinfo.org
7. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
8. Onyx Pharmaceuticals Announces Investor Teleconference and Webcast
9. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference
10. ADVENTRX Pharmaceuticals Announces Closing of Financing
11. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... -- Dr. Keesha Ewers of The Functional ... flibanserin, or what is being touted as "pink ... female sexual desire back several decades. Diminished libido ... libido as a singular symptom with a singular ... Photo - http://photos.prnewswire.com/prnh/20150804/254705 ...
(Date:8/4/2015)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company focused ... today that Daniel P. Gold , Ph.D., President and ... Healthcare Conference on Tuesday, August 11, 2015 at 3:40 p.m. ... New York . A live webcast of the ... will be available approximately one hour after the presentation. ...
(Date:8/4/2015)... YORK , Aug. 4, 2015  Delcath Systems, ... medical device company focused on oncology with an emphasis ... announces that two abstracts summarizing data from studies in ... treatment with the Delcath Hepatic CHEMOSAT ® Delivery ... of Dermato Oncology (EADO) annual congress, which will be held ...
Breaking Medicine Technology:Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4
... NEW YORK, July 5, 2011 ORBIS and its ... intensive three-week program in Ulaanbaatar, Mongolia (June 19 - ... – a state-of-the-art hospital with wings. The mission was ... care, and included a three-week ophthalmic skills exchange and ...
... Oncimmune ® LLC, maker of EarlyCDT™-Lung , a simple ... early detection of lung cancer , today announces that an abstract ... of 1,000 patients in clinical practice" supports the previously ... non-small cell lung cancer (NSCLC) at least as high as in ...
Cached Medicine Technology:ORBIS International's Flying Eye Hospital Brings Sight Saving Skills and Technology to Ulaanbaatar, Mongolia 2ORBIS International's Flying Eye Hospital Brings Sight Saving Skills and Technology to Ulaanbaatar, Mongolia 3ORBIS International's Flying Eye Hospital Brings Sight Saving Skills and Technology to Ulaanbaatar, Mongolia 4First Reportable Data of EarlyCDT™-Lung Use in Clinical Practice Presented at IASLC World Conference on Lung Cancer 2First Reportable Data of EarlyCDT™-Lung Use in Clinical Practice Presented at IASLC World Conference on Lung Cancer 3First Reportable Data of EarlyCDT™-Lung Use in Clinical Practice Presented at IASLC World Conference on Lung Cancer 4First Reportable Data of EarlyCDT™-Lung Use in Clinical Practice Presented at IASLC World Conference on Lung Cancer 5
(Date:8/4/2015)... Horeb, WI (PRWEB) , ... August 04, 2015 , ... ... released video on the subject, Renew Man™ is standing up as a voice of ... 15-year veteran of the healthy aging industry with special experience and expertise in the ...
(Date:8/4/2015)... ... , ... 24/7 Care At Home , a provider of comprehensive home ... that the U.S. Department of Veteran’s Affairs (VA) has awarded its agency a rating ... on the path to meeting the aspirational goals the VA promotes each year. ...
(Date:8/4/2015)... ... 2015 , ... Buckeye Health Plan is reminding parents to ... covered for members under the Healthchek program . , “Many schools have ... immunizations may not be allowed to attend when school begins in August,” said ...
(Date:8/4/2015)... ... August 04, 2015 , ... Discovia, ... entities, today announced that John Munro, a 15-year veteran of the eDiscovery services ... Services Operations. , “I am thrilled to join Discovia at this important point ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... today announced that Bruce McCalley joins its executive leadership team as Senior Vice ... sales success at technology companies and expanding global markets with a special emphasis ...
Breaking Medicine News(10 mins):Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3
... March 13 Kensey Nash Corporation (Nasdaq: ... Thirteenth Annual New York Emerging Growth Institutional Investor Forum ... Tuesday, March 24, 2009.Joseph W. Kaufmann, Kensey Nash,s CEO, ... a.m. (ET). The presentation materials will be available ...
... Parkinson Disease Association (APDA) and the National Parkinson Foundation ... Onset Parkinson Conferences; First to be held in Dallas, ... The American Parkinson Disease Association,s (APDA) National ... Young Onset Parkinson Network announced their first joint collaboration ...
... options are roadblocks to smartest decision, report says , , ... the staggering choices of drug plans available through Medicare ... new report says. , The report found that the ... should let people pick the best value for their ...
... ROCKVILLE, Md., March 13 Human Genome Sciences, Inc. ... presentation at the Cowen and Company 29th Annual Health ... at www.hgsi.com .(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) , ... will present a corporate overview on Wednesday, March 18, ...
... Facility with TD Bank, N.A.BASKING RIDGE, N.J., March 13 ... results for the fourth quarter and year ended December 31, ... revenues decreased 7.7% to $47.4 million compared to $51.4 million ... net income of $1.2 million for the fourth quarter of ...
... New York Stock Exchange Bell-Ringing, Yoko Ono Lennon Event at the ... , ... New York, NY (PRWEB) March 13, 2009 ... today announced a series of national and international events to mark ...
Cached Medicine News:Health News:Young Onset Parkinson Conferences: A First-Ever Collaboration 2Health News:Young Onset Parkinson Conferences: A First-Ever Collaboration 3Health News:Many Seniors Not Selecting Lowest Cost Medicare Drug Plans 2Health News:Many Seniors Not Selecting Lowest Cost Medicare Drug Plans 3Health News:Hooper Holmes Announces Fourth Quarter and Year-End 2008 Results 2Health News:Hooper Holmes Announces Fourth Quarter and Year-End 2008 Results 3Health News:Hooper Holmes Announces Fourth Quarter and Year-End 2008 Results 4Health News:Hooper Holmes Announces Fourth Quarter and Year-End 2008 Results 5Health News:Hooper Holmes Announces Fourth Quarter and Year-End 2008 Results 6Health News:Hooper Holmes Announces Fourth Quarter and Year-End 2008 Results 7Health News:Hooper Holmes Announces Fourth Quarter and Year-End 2008 Results 8Health News:Autism Speaks Celebrates Second Annual World Autism Awareness Day with an Array of International Events on April 2 2Health News:Autism Speaks Celebrates Second Annual World Autism Awareness Day with an Array of International Events on April 2 3Health News:Autism Speaks Celebrates Second Annual World Autism Awareness Day with an Array of International Events on April 2 4Health News:Autism Speaks Celebrates Second Annual World Autism Awareness Day with an Array of International Events on April 2 5
... our coat apron, weight is distributed ... of comfortable wear without fatigue. Made ... our front closing special procedure apron ... closures that make it a cinch ...
... has always been a popular choice. Thats ... take-off. Our new design is even more ... two velcro closures to adjust the fit ... to fully protect your neck. All .5mm ...
... feature a 2 adjustable belt buckle. You adjust ... the Apron off your shoulders. And now theres ... the female anatomy. ,For additional back support try ... reduce pressure on the vertebrae and help lift ...
The Easy Wrap Apron is now available with an attached Thyroid Collar. The Thyroid Collar is held on with velcro so it adjusts to fully protect the neck. This Apron with Collar is available in 5mm lea...
Medicine Products: